Collectively these data emphasize that BCL2 status is predictive of venetoclax efficacy in NHL not only as a single agent, but also in the adjuvant setting with anti-tumorigenic agents that modulate MCL-1 levels. This evidence concerns the gene MCL1 and non-Hodgkin lymphoma.